BP
ELV icon

Ballentine Partners’s Elevance Health ELV Stock Holding History

Ballentine Partners’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$649K Buy
1,679
+651
+63% +$241K 0.01% 483
2026
Q1 		$301K Sell
1,028
-374
-27% -$123K ﹤0.01% 737
2025
Q4 		$491K Buy
1,402
+4
+0.3% +$1.35K 0.01% 511
2025
Q3 		$452K Buy
1,398
+187
+15% +$58.2K 0.01% 544
2025
Q2 		$471K Sell
1,211
-840
-41% -$338K 0.01% 506
2025
Q1 		$892K Buy
2,051
+360
+21% +$145K 0.02% 318
2024
Q4 		$624K Sell
1,691
-611
-27% -$256K 0.01% 377
2024
Q3 		$1.2M Sell
2,302
-345
-13% -$184K 0.02% 248
2024
Q2 		$1.43M Buy
2,647
+673
+34% +$356K 0.03% 204
2024
Q1 		$1.02M Buy
1,974
+78
+4% +$38.8K 0.02% 246
2023
Q4 		$894K Sell
1,896
-37
-2% -$17.1K 0.02% 246
2023
Q3 		$842K Sell
1,933
-36
-2% -$16.3K 0.02% 217
2023
Q2 		$875K Sell
1,969
-137
-7% -$63.2K 0.02% 213
2023
Q1 		$968K Buy
2,106
+53
+3% +$25.2K 0.02% 196
2022
Q4 		$1.05M Buy
2,053
+183
+10% +$92.9K 0.03% 164
2022
Q3 		$849K Buy
1,870
+264
+16% +$126K 0.03% 173
2022
Q2 		$774K Buy
1,606
+10
+0.6% +$4.95K 0.03% 181
2022
Q1 		$784K Buy
1,596
+23
+1% +$10.5K 0.02% 201
2021
Q4 		$729K Sell
1,573
-36
-2% -$15.1K 0.02% 219
2021
Q3 		$600K Buy
1,609
+22
+1% +$8.36K 0.02% 213
2021
Q2 		$606K Sell
1,587
-157
-9% -$60K 0.02% 210
2021
Q1 		$627K Buy
1,744
+125
+8% +$40.2K 0.02% 196
2020
Q4 		$520K Sell
1,619
-484
-23% -$149K 0.02% 215
2020
Q3 		$565K Buy
2,103
+157
+8% +$42.2K 0.03% 195
2020
Q2 		$512K Sell
1,946
-82
-4% -$21.9K 0.02% 205
2020
Q1 		$459K Sell
2,028
-74
-4% -$20.2K 0.03% 196
2019
Q4 		$635K Sell
2,102
-27
-1% -$7.43K 0.03% 197
2019
Q3 		$511K Sell
2,129
-93
-4% -$25.5K 0.02% 207
2019
Q2 		$627K Buy
2,222
+644
+41% +$176K 0.03% 192
2019
Q1 		$452K Buy
1,578
+22
+1% +$6.36K 0.02% 201
2018
Q4 		$409K Sell
1,556
-119
-7% -$32.7K 0.02% 203
2018
Q3 		$459K Buy
1,675
+28
+2% +$7.27K 0.02% 207
2018
Q2 		$393K Buy
1,647
+210
+15% +$48.6K 0.02% 217
2018
Q1 		$316K Buy
1,437
+17
+1% +$3.99K 0.02% 248
2017
Q4 		$320K Sell
1,420
-71
-5% -$15.1K 0.02% 255
2017
Q3 		$284K Sell
1,491
-56
-4% -$10.7K 0.02% 279
2017
Q2 		$290K Buy
1,547
+124
+9% +$22.3K 0.02% 282
2017
Q1 		$235K Buy
+1,423
New +$226K 0.02% 211
2016
Q4 		– Sell
-1,281
Closed -$162K – 212
2016
Q3 		$162K Sell
1,281
-159
-11% -$20.5K 0.01% 185
2016
Q2 		$188K Sell
1,440
-83
-5% -$11.4K 0.02% 209
2016
Q1 		$212K Buy
+1,523
New +$204K 0.02% 196
2015
Q3 		– Sell
-1,235
Closed -$203K – 158
2015
Q2 		$203K Buy
+1,235
New +$197K 0.02% 156

Other funds holding ELV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
HGIM
High Ground Investment Management London, United Kingdom $1.14B AUM 29.32% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CF
Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MIHAS
Maj Invest Holding A/S Copenhagen K, Denmark $2.2B AUM 25.64% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

Ballentine Partners's ELV Position: Q2 2026 in Review

Ballentine Partners increased its Elevance Health (ELV) stake by 63% in Q2 2026, buying an estimated $241K and bringing the position to 1,679 shares worth $649K. The position accounts for 0.01% of the portfolio, ranked #483.

Ballentine Partners first reported a position in ELV in Q2 2015 and has held it in 42 quarters since. The position peaked at $1.43M in Q2 2024. 258 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Ballentine Partners held 1,679 shares of Elevance Health worth $649K as of Q2 2026.
  • Ballentine Partners bought 651 Elevance Health shares in Q2 2026, an estimated $241K.
  • Elevance Health made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #483 holding.
  • Ballentine Partners first reported a position in Elevance Health in Q2 2015 and has held it in 42 quarters since.
  • Ballentine Partners's Elevance Health position peaked at $1.43M in Q2 2024.
  • 258 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.